Status:
COMPLETED
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
COPD
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
Eligibility Criteria
Inclusion
- COPD
- Current or exsmokers, 10 pack years
Exclusion
- Asthma
- Any clinically relevant abnormal findings at screening examinations
- Recent COPD exacerbation
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
329 Patients enrolled
Trial Details
Trial ID
NCT00929708
Start Date
June 1 2009
End Date
March 1 2010
Last Update
February 17 2014
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Blagoevgrad, Bulgaria
2
Research Site
Pleven, Bulgaria
3
Research Site
Rousse, Bulgaria
4
Research Site
Sofia, Bulgaria